TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05070728

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injector
Description: Intravitreal sham injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAI Insert
Description: Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle.
Study: NCT05183893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 5 g of L-citruline + 5 g of additives

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline-malate
Description: 8g of citrulline-malate + 2 g of additives

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g of maltodextrine
Study: NCT05428098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Oral and written education according to the life model
Study: NCT04900623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.
Study: NCT06236880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-2505
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-2505
Description: IV
Study: NCT05530811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5% bupivacaine
Study: NCT05689697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PanTrek
Description: administration of exogenouse keton body

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PanTrek
Description: administration of exogenouse keton body
Study: NCT04769310

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac and Brain MRI
Description: A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI
Study: NCT06310044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal irrigant Commiphora Myrrh 50%
Description: Root canal irrigant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal irrigant Commiphora Myrrh 50%
Description: Root canal irrigant
Study: NCT05969431

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of cortisol level
Description: We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of cortisol level
Description: We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of cortisol level
Description: We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.
Study: NCT06557174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-002
Description: intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil， MMF
Description: daily oral 0.2g
Study: NCT04728451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle wear support
Description: Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
Study: NCT06187428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PainSMART-strategy
Description: Be PainSMART:er is a seven minute long film developed by the research group based on modern pain science and previous qualitative studies.~The film is divided into three sections:~Section 1- Educates that MSKP is a complex protective system that does not reflect the anatomical state of the body and provides reassurance that MSKP is rarely caused by serious pathology.~Section 2- Provides advice on active MSKP coping, such as encouraging work despite some pain, in an attempt to reconceptualise the belief that a painful body part needs to be rested.~Section 3- Aims to prepare patients for a biopsychosocial physiotherapy consultation by encouraging them to reflect on the film's messages.~In addition to the film, the questions posed to the participant at the initial consultation aim to facilitate the discussion around the film and MSKP reflections. Management subsequent to the initial consultation will follow usual management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy management
Description: Patients randomised to the control group follow usual MSKP physiotherapy management. Specifically, patients first contact their physiotherapy department online or via telephone and are triaged by a certified physiotherapist and are booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients in the control group receive online data collection questionnaires identical to those of the intervention group at baseline and prior to the consultation, excluding the film and the questions linked to the film. The initial consultation will take place as usual according to the preferences of the physiotherapist. The physiotherapist will pose one question at start of the consultation to acknowledge the completion of control group questionnaires. Management subsequent to the initial consultation will follow usual management.
Study: NCT05249465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core behavioral weight loss intervention
Description: All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely.
Study: NCT06532383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07940369
Description: Bulk powder for extemporaneous preparation for oral solutions.
Study: NCT05873439

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Genomically Guided Radiation Therapy (RT)
Description: Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Genomically Guided Radiation Therapy (RT)
Description: Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Genomically Guided Radiation Therapy (RT)
Description: Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
Study: NCT05135663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
Study: NCT05201924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime routine
Description: a regular routine conducted around bedtime includes brush, book reading and regular bedtime

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: a healthy control checklist
Study: NCT06369467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linvoseltamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Administered by subcutaneous (SC) injection
Study: NCT03690011

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD7.CAR/28zeta CAR T cells
Description: Three dose levels will be evaluated:~* Dose level one: 1×10\^7 cells/m\^2~* Dose level two: 3×10\^7 cells/m\^2~* Dose level three: 5x10\^7 cells/m\^2~* Dose level four: 1×10\^8 cells/m\^2
Study: NCT06388434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Arm Balance Response Training
Description: Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
Study: NCT06419179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg i.v. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID orally
Study: NCT05922553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Ingredient Mukbang
Description: Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common Mukbang
Description: Common Mukbang videos made and uploaded by the famous Mukbang makers.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General short videos
Description: Short videos that don't contain any food cues.
Study: NCT06248411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK2260
Description: KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK2260
Description: KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
Study: NCT05350501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EO2040
Description: EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC.
Study: NCT06457269

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by three human doctors
Description: This intervention involves answering patient inquiries by different human doctors. Each patient is randomly assigned by the system to three doctors from different provinces in China selected from the database of doctors. The doctors all come from multiple online consultation platforms in China, and their diagnostic qualifications and medical licenses have undergone strict verification.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by three human doctors
Description: This intervention involves answering patient inquiries by different human doctors. Each patient is randomly assigned by the system to three doctors from different provinces in China selected from the database of doctors. The doctors all come from multiple online consultation platforms in China, and their diagnostic qualifications and medical licenses have undergone strict verification.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-3.5 (with search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-3.5 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-3.5 (with search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-3.5 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-3.5 (without search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-3.5 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-3.5 (without search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-3.5 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-4.0 (with search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-4.0 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study: NCT06011967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intubation using C-MAC D blade videolariyngoscope
Description: all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intubation using C-MAC D blade videolariyngoscope
Description: all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intubation using C-MAC D blade videolariyngoscope
Description: all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.
Study: NCT06457269

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-4.0 (with search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-4.0 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study: NCT05530811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 0.5% bupivacaine
Study: NCT05635630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA and adjuvant therapy
Description: Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA
Description: Patients of ctDNA negative group are monitored by ctDNA every 3 months.
Study: NCT06496503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity Protocol
Description: The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
Study: NCT05672108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized Oil
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tris-acryl Gelatin Microspheres
Description: Given IA
Study: NCT05103527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation
Description: Stimulation at L2, L3, L4 and S1 spinal levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation
Description: Stimulation at L2, L3, L4 and S1 spinal levels
Study: NCT05646277

Intervention type: OTHER
Intervention: e-Consultation
Description: first orthodontic consultation in remote

Intervention type: OTHER
Intervention: Consultation
Description: first orthodontic consultation in face-to-face